{"transactions":[{"id":4634300,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2026-10-03T00:30:31.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":false,"shares":50246,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The option was granted to and is held by Futurum through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer."}],"balance_after":344983,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":50246},"source":{"system":"sec-edgar","filing":"0001193125-26-412431","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526412431/ownership.xml","form_type":"4"}},{"id":4634299,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-10-03T00:30:31.000Z","date":"2026-09-30","kind":"sale","planned":true,"acquired":false,"shares":50246,"price":25.03,"value":1257657.38,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.10 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Ordinary Shares are held by Futurum B.V. (\"Futurum\") through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum."}],"balance_after":69302,"source":{"system":"sec-edgar","filing":"0001193125-26-412431","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526412431/ownership.xml","form_type":"4"}},{"id":4634298,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-10-03T00:30:31.000Z","date":"2026-09-30","kind":"exercise","planned":true,"acquired":true,"shares":50246,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Ordinary Shares are held by Futurum B.V. (\"Futurum\") through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum."}],"balance_after":119548,"source":{"system":"sec-edgar","filing":"0001193125-26-412431","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526412431/ownership.xml","form_type":"4"}},{"id":676283,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2026-08-25T20:30:07.000Z","date":"2026-08-24","kind":"exercise","planned":true,"acquired":false,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The option was granted to and is held by Futurum through PoolCo for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer."}],"balance_after":395229,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001193125-26-365202","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526365202/ownership.xml","form_type":"4"}},{"id":676282,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-08-25T20:30:07.000Z","date":"2026-08-24","kind":"sale","planned":true,"acquired":false,"shares":125000,"price":26.91,"value":3363750.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.72 to $27.70 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Ordinary Shares are held by Futurum B.V. (\"Futurum\") through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum."}],"balance_after":69302,"source":{"system":"sec-edgar","filing":"0001193125-26-365202","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526365202/ownership.xml","form_type":"4"}},{"id":676281,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-08-25T20:30:07.000Z","date":"2026-08-24","kind":"exercise","planned":true,"acquired":true,"shares":125000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These Ordinary Shares are held by Futurum B.V. (\"Futurum\") through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum."}],"balance_after":194302,"source":{"system":"sec-edgar","filing":"0001193125-26-365202","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526365202/ownership.xml","form_type":"4"}},{"id":853842,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":101409,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The option was granted to and is held by Futurum through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer."}],"balance_after":520229,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":101409},"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853841,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-06","kind":"exercise","planned":true,"acquired":false,"shares":94124,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The option was granted to and is held by Futurum through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer."}],"balance_after":621638,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":94124},"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853840,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-05","kind":"exercise","planned":true,"acquired":false,"shares":104467,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The option was granted to and is held by Futurum through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the Issuer."}],"balance_after":715762,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":104467},"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853839,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":101409,"price":30.29,"value":3071678.61,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 per share to $30.80 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum."}],"balance_after":69302,"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853838,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":101409,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum."}],"balance_after":170711,"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853837,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-06","kind":"sale","planned":true,"acquired":false,"shares":94124,"price":30.32,"value":2853839.68,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 per share to $30.42 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum."}],"balance_after":69302,"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853836,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-06","kind":"exercise","planned":true,"acquired":true,"shares":94124,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum."}],"balance_after":163426,"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853835,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":104467,"price":30.3,"value":3165350.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 per share to $30.55 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum."}],"balance_after":69302,"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":853834,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-10T00:18:01.000Z","date":"2026-03-05","kind":"exercise","planned":true,"acquired":true,"shares":104467,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum."}],"balance_after":173769,"source":{"system":"sec-edgar","filing":"0001193125-26-099073","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526099073/ownership.xml","form_type":"4"}},{"id":885368,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-24T21:40:11.000Z","date":"2026-02-20","kind":"sale","planned":false,"acquired":false,"shares":30789,"price":35.46,"value":1091777.94,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.24 to $35.86 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":53500,"source":{"system":"sec-edgar","filing":"0001193125-26-067260","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526067260/ownership.xml","form_type":"4"}},{"id":885367,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-02-24T21:40:11.000Z","date":"2026-02-20","kind":"sale","planned":false,"acquired":false,"shares":14692,"price":35,"value":514220.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.24 to $35.23 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":84289,"source":{"system":"sec-edgar","filing":"0001193125-26-067260","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526067260/ownership.xml","form_type":"4"}},{"id":944831,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2026-01-07T23:31:26.000Z","date":"2026-01-07","kind":"grant","planned":true,"acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares underlying the option will vest on Janaury 2, 2027, the one-year anniversary of the vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":115000,"derivative":{"exercise_price":35.45,"expiration_date":"2036-01-07","underlying":"Ordinary Shares","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001193125-26-006662","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526006662/ownership.xml","form_type":"4"}},{"id":944830,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-07T23:31:26.000Z","date":"2026-01-07","kind":"grant","planned":true,"acquired":true,"shares":25500,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents RSUs, each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each RSU was granted on January 7, 2026 for no consideration."}],"balance_after":98981,"source":{"system":"sec-edgar","filing":"0001193125-26-006662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526006662/ownership.xml","form_type":"4"}},{"id":944829,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2026-01-07T23:31:26.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":33.25,"value":199500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents pre-arranged sale of shares by the Reporting Person solely to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units (RSUs) pursuant to sell-to-cover agreement entered into with the Issuer. The sale does not represent a discretionary transaction by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.77 to $33.58 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."}],"balance_after":73481,"source":{"system":"sec-edgar","filing":"0001193125-26-006662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000119312526006662/ownership.xml","form_type":"4"}},{"id":1056937,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2025-08-25T21:04:16.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":7658,"price":25.49,"value":195202.42,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.39 per share to $25.62 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The ordinary shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the ordinary shares held by Futurum."}],"balance_after":69302,"source":{"system":"sec-edgar","filing":"0000950170-25-111241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017025111241/ownership.xml","form_type":"4"}},{"id":1056936,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2025-08-25T21:04:16.000Z","date":"2025-08-22","kind":"sale","planned":false,"acquired":false,"shares":42342,"price":25.08,"value":1061937.36,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.39 per share to $25.35 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The ordinary shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the ordinary shares held by Futurum."}],"balance_after":76960,"source":{"system":"sec-edgar","filing":"0000950170-25-111241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017025111241/ownership.xml","form_type":"4"}},{"id":1056935,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2025-08-25T21:04:16.000Z","date":"2025-08-21","kind":"sale","planned":false,"acquired":false,"shares":50000,"price":24.29,"value":1214500.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.73 per share to $24.57 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The ordinary shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the ordinary shares held by Futurum."}],"balance_after":119302,"source":{"system":"sec-edgar","filing":"0000950170-25-111241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017025111241/ownership.xml","form_type":"4"}},{"id":1188957,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-03-28T21:20:10.000Z","date":"2025-03-26","kind":"exercise","planned":false,"acquired":false,"shares":45481,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the BCA. The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon grant, all of the RSUs were fully-vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon grant, all of the RSUs were fully-vested."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":45481},"source":{"system":"sec-edgar","filing":"0000950170-25-046947","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017025046947/ownership.xml","form_type":"4"}},{"id":1188956,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-03-28T21:20:10.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":45481,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the BCA. The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Upon grant, all of the RSUs were fully-vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Upon grant, all of the RSUs were fully-vested."}],"balance_after":45481,"derivative":{"underlying":"Ordinary Shares","underlying_shares":45481},"source":{"system":"sec-edgar","filing":"0000950170-25-046947","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017025046947/ownership.xml","form_type":"4"}},{"id":1188955,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-28T21:20:10.000Z","date":"2025-03-26","kind":"exercise","planned":false,"acquired":true,"shares":45481,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":79481,"source":{"system":"sec-edgar","filing":"0000950170-25-046947","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017025046947/ownership.xml","form_type":"4"}},{"id":1188954,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-28T21:20:10.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":19302,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects ordinary shares issued to Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person on March 26, 2025 as earnout shares pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the \"BCA\"). The BCA provided that certain shareholders would receive additional ordinary shares of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of November 22, 2022, the date of closing under the BCA (the \"Closing Date\"). Futurum's right to receive the earnout shares became fixed and irrevocable on the Closing Date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The ordinary shares are held by Futurum for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the ordinary shares held by Futurum."}],"balance_after":169302,"source":{"system":"sec-edgar","filing":"0000950170-25-046947","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017025046947/ownership.xml","form_type":"4"}},{"id":1191097,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2025-03-26T20:27:40.000Z","date":"2025-03-24","kind":"exercise","planned":false,"acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is 1.16392 Euros."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The option was granted to and is held by Futurum through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the securities held by Futurum through PoolCo. PoolCo has no voting or investment control or pecuniary interest in the securities held on behalf of Futurum. Upon exercise of the option, the Ordinary Shares were issued to Futurum directly, pursuant to a written agreement among Futurum, PoolCo and the issuer."}],"balance_after":820229,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000950170-25-045283","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017025045283/ownership.xml","form_type":"4"}},{"id":1191096,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-26T20:27:40.000Z","date":"2025-03-24","kind":"exercise","planned":false,"acquired":true,"shares":150000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is 1.16392 Euros."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investment control over the Ordinary Shares held by Futurum."}],"balance_after":150000,"source":{"system":"sec-edgar","filing":"0000950170-25-045283","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017025045283/ownership.xml","form_type":"4"}},{"id":1308389,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2025-01-07T22:21:06.000Z","date":"2025-01-07","kind":"grant","planned":false,"acquired":true,"shares":34000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. 1/3 of the RSUs will vest on each of the first, second and third anniversaries of the vesting start date, subject to the Reporting Person's continued service through each such date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU was granted on January 7, 2025 for no consideration."}],"balance_after":34000,"source":{"system":"sec-edgar","filing":"0000950170-25-003018","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017025003018/ownership.xml","form_type":"4"}},{"id":1311193,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2025-01-06T22:48:27.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option will vest on January 2, 2026, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":200000,"derivative":{"exercise_price":25.96,"expiration_date":"2035-01-02","underlying":"Ordinary Shares","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000950170-25-002356","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017025002356/ownership.xml","form_type":"4"}},{"id":1559743,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2024-03-27T20:30:16.000Z","date":"2024-03-26","kind":"exercise","planned":false,"acquired":false,"shares":201673,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was granted on November 22, 2022 to replace an option originally granted on July 6, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 292,214 of the shares underlying the option immediately vested on the grant date. 25% of the remaining shares underlying the option vested on January 1, 2021, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The option was granted to and is held by Futurum through PoolCo for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investement control over the securities held by Futurum through PoolCo. PoolCo has no voting or investement control or pecuniary interest in the securities held on behalf of Futurum."}],"balance_after":970229,"derivative":{"expiration_date":"2031-07-06","underlying":"Ordinary Shares","underlying_shares":201673},"source":{"system":"sec-edgar","filing":"0000950170-24-037241","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017024037241/ownership.xml","form_type":"4"}},{"id":1559742,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2024-03-27T20:30:16.000Z","date":"2024-03-26","kind":"sale","planned":false,"acquired":false,"shares":190476,"price":21.5,"value":4095234.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"These shares were sold in multiple transactions at a price of $21.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F5","text":"The Ordinary Shares were sold by the Reporting Person pursuant to an exemption in a lock-up agreement, dated February 12, 2024, in order to satisfy certain tax liabilities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investement control over the Ordinary Shares held by Futurum through PoolCo. PoolCo has no voting or investement control or pecuniary interest in the Ordinary Shares held on behalf of Futurum."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-037241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017024037241/ownership.xml","form_type":"4"}},{"id":1559741,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2024-03-27T20:30:16.000Z","date":"2024-03-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":11197,"price":22.72,"value":254395.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents Ordinary Shares that were withheld to satisfy the exercise price due upon the exercise of the options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investement control over the Ordinary Shares held by Futurum through PoolCo. PoolCo has no voting or investement control or pecuniary interest in the Ordinary Shares held on behalf of Futurum."}],"balance_after":190476,"source":{"system":"sec-edgar","filing":"0000950170-24-037241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017024037241/ownership.xml","form_type":"4"}},{"id":1559740,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Ordinary Shares","published_at":"2024-03-27T20:30:16.000Z","date":"2024-03-26","kind":"exercise","planned":false,"acquired":true,"shares":201673,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The exercise price of the option is EUR 1.16392."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Ordinary Shares are held by Futurum B.V. (\"Futurum\") through NAP PoolCo B.V. (\"PoolCo\") for the benefit of the Reporting Person. The Reporting Person exercises sole voting and investement control over the Ordinary Shares held by Futurum through PoolCo. PoolCo has no voting or investement control or pecuniary interest in the Ordinary Shares held on behalf of Futurum."}],"balance_after":201673,"source":{"system":"sec-edgar","filing":"0000950170-24-037241","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017024037241/ownership.xml","form_type":"4"}},{"id":1693432,"issuer":{"id":1826,"kind":"organization","name":"NewAmsterdam Pharma Co N.V.","symbol":"NAMS"},"owners":[{"id":19969,"kind":"person","name":"Kastelein Johannes Jacob Pieter","position":1,"cik":"0002000389","reported_name":"Kastelein Johannes Jacob Pieter","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Option (right to buy)","published_at":"2024-01-03T22:17:03.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option will vest on January 1, 2025, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date."}],"balance_after":500000,"derivative":{"exercise_price":11.17,"expiration_date":"2034-01-01","underlying":"Ordinary Shares","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000950170-24-001125","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2000389/000095017024001125/ownership.xml","form_type":"4"}}]}